The 2026 Approval Outlook for GLP-1 and Peptide Sellers

When the FDA declared tirzepatide no longer in shortage in October 2024 and semaglutide followed in February 2025, it did not shut the door on compounding pharmacies and peptide sellers - but it did change the conversation entirely. Processors who had approved GLP-1 accounts with minimal documentation started revisiting their underwriting criteria. FDA Commissioner Makary's February 2026 enforcement statement made clear that entities marketing unapproved compounded GLP-1 products should expect legal action. In 2026, the question underwriters are asking has shifted from "what are you selling" to "can you prove how you source it and what you are claiming about it." That distinction is what most payment content in this space is still missing.

What the FDA Shortage Resolution Actually Changed for Sellers

The compounding pharmacies that built GLP-1 businesses during the shortage years operated under a regulatory safe harbor: when a drug is on the FDA shortage list, certain compounding exemptions apply. That safe harbor expired. The FDA's tirzepatide determination came first in October 2024, with semaglutide following in February 2025 - and the grace periods (60 days for 503A pharmacies, 90 days for 503B facilities) were shorter than many operators expected.

For payment processors, this mattered immediately. The legal basis for mass compounding had evaporated, and the market made that visible fast. As The Peptide List noted in early 2026, the telehealth and compounding ecosystem that flourished during shortage years "has largely contracted or pivoted to other services." Eli Lilly had been sending cease-and-desist letters to telehealth companies since August 2025. Thirty-eight state attorneys general sent a joint letter to the FDA in February 2025 demanding action on counterfeit GLP-1 products.

From my perspective at SeamlessChex, the GLP-1 accounts we have continued to approve through this period share one quality: a clear paper trail from licensed supplier to final product. The businesses that came through the 2025 transition intact had built that documentation foundation before regulators required it.

What the FDA Shortage Resolution Actually Changed for Sellers refers to a structured approach to what the fda shortage resolution actually changed for sellers that directly impacts operational efficiency and outcomes.

What Underwriters Look For Now

If you are applying for a merchant account as a GLP-1 or peptide seller in 2026, expect underwriters to focus on three areas:

• Sourcing documentation. Where are your compounds coming from? Underwriters want to see certificates of analysis (COAs), licensed supplier agreements, and evidence of CGMP-compliant sourcing. Third-party testing substantiated by an accredited lab - not just the supplier's own paperwork - carries meaningful weight. A 2026 review of 550+ peptide providers found roughly 40% showed at least one significant red flag, and about 1 in 8 had COAs that testing laboratories could not independently verify. Underwriters know this data.
• Marketing and claims review. What are you saying about your products? Underwriters will pull your website, email sequences, and sometimes social content. Therapeutic claims that imply a product diagnoses, treats, or cures a condition are a major flag. FDA-compliant language matters more in 2026 than it did in 2024.
• Business structure and credentials. A licensed pharmacy or telehealth platform with a processing history carries a different risk profile than a startup with no track record. State regulatory oversight is expanding, too - Indiana's 2027 med spa bill now requires Board of Pharmacy registration and tighter scrutiny of compounded product sourcing.

None of these requirements are impossible to meet. Sellers who built compliant operations during the regulatory uncertainty of 2024 and 2025 are well positioned. The friction in 2026 falls almost entirely on those who did not.

How SeamlessChex Evaluates GLP-1 and Peptide Sellers

SeamlessChex is a credit card processing platform built for GLP-1 sellers, compounding pharmacies, and nutraceutical businesses. We process payments for this vertical through regulatory cycles, and we understand what a legitimate operation looks like - and what the acquiring banks behind us need to see.

Our underwriting team reviews GLP-1 and peptide applications with a practical lens. We want to see sourcing documentation and compliant marketing not because we are creating obstacles, but because those are the same standards our banking partners apply. Getting approved with us means your documentation package has already been vetted against what banks will actually accept.

SeamlessChex works with established businesses processing a minimum of $25,000 per month. If you are at that volume and your compliance documentation is in order, the approval process is more straightforward than most sellers in this space expect. We are not figuring out your industry as we go - we know the vertical, and we know what a reviewable application looks like.

For a detailed breakdown of what high-risk underwriters actually ask for, the deep dive at What Documentation High-Risk Underwriters Actually Need to Approve Your Application covers the full documentation checklist.

What Will Matter Most in the Next 12 to 24 Months

The regulatory environment for GLP-1 and peptide products will keep moving. Here is where I expect the underwriting focus to land through mid-2027:

• FDA enforcement actions will narrow the field. Every enforcement action the FDA takes against a non-compliant compounder adds to the category's risk profile in underwriting. Sellers who can document their distance from non-compliant actors - through supplier vetting, COA chains, and independent third-party testing - will maintain better processor relationships than those who cannot.
• Chargeback rates remain the persistent pressure point. GLP-1 and peptide products attract buyers with high expectations, and disputes rise when results or delivery do not match. Keeping dispute ratios below 1% requires proactive customer communication, clear refund policies, and consistent product quality. This metric draws more underwriter attention than almost anything else.
• Subscription and continuity billing stays under scrutiny. If you run recurring charges, your consent language and cancellation flows need to be airtight. The FTC and state attorneys general are actively looking at this billing model, and underwriters know it.

The sellers who thrive through 2027 will be the ones who treat compliance as a competitive advantage - not a cost center.

The 2025 FDA shortage resolution reshuffled the deck for GLP-1 and peptide sellers - but it did not close the game. Businesses with compliant sourcing, clean marketing, and solid processing history are getting approved in 2026. The ones facing friction are those that did not build their documentation foundation during the years when it was easier to operate without one. If you have done that work, the approval path is clearer than most in this space believe. We work with businesses in this vertical every day, and we know the difference between a reviewable application and one that stalls.